Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
240actual
Sites
1
Country
Poland
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-01 | actual | When the study began enrolling |
| Primary completion | 2026-01-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-20 | actual | The whole study's end, after follow-up |
| First posted | 2026-04-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer
Intervention
- Combination product: Nivolumab + Ipilimumab + Chemotherapy
Primary outcomes
what the primary-completion date above is the date OFSecond-line systemic anticancer treatment prescribed after progression/discontinuation of first-line therapy
measured Up to 26 months
Third-line systemic anticancer treatment prescribed after progression/discontinuation of second-line therapy
measured Up to 26 months
Overall Response Rate (ORR) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
measured Up to 26 months
Disease Control Rate (DCR) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
measured Up to 26 months
Progression-Free Survival (PFS)
measured Up to 26 months
Duration of Response (DOR) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
measured Up to 26 months
Overall Survival (OS)
measured Up to 26 months
Duration of Treatment
measured Up to 26 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed